Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Pfizer Inc (PFE) vs Wayfair Inc (W) Price & Performance

Pfizer IncTrade
Wayfair IncTrade

Price performance (Past 24H)

Key statistics

Pfizer Inc vs Wayfair Inc — how do they compare? Pfizer Inc trades at $27.9 (market cap $158.39B), while Wayfair Inc trades at $100.12 (market cap $13.69B). The key difference: Pfizer Inc is far larger — about 11.6× Wayfair Inc's market cap, and Pfizer Inc pays a 6.19% dividend while Wayfair Inc pays none. Which is the better fit depends on your goals.

PFEW
Market Cap
$158.39B$13.69B
Volume
29,869,932
Sector
HealthConsumer Cyclical
52-Week High
$29.02$119.05
52-Week Low
$23.60$57.40
Enterprise Value
$209.89B$16.03B
Dividend Yield
6.19%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Pfizer Inc

Pfizer (PFE) trades at $27.78, down 2.36% today, with a consensus price target of $28.33 suggesting modest upside. The stock shows mixed technical signals with bullish moving averages but neutral oscillators. Recent earnings have consistently beaten expectations, though revenue declined from pandemic peaks. The company maintains strong cash flow generation and a solid dividend yield of approximately 3.1%.

Pfizer presents a value opportunity with reasonable valuation metrics and dividend stability, but faces headwinds from post-COVID revenue normalization and patent expirations. The company's pipeline progress in obesity and oncology could drive future growth, though execution risks remain. Analyst sentiment leans cautious with 59% hold ratings.

Wayfair Inc

Wayfair (W) trades at $99.96, up 0.53% today, with a bullish technical signal supported by moving averages. The stock shows strong revenue growth of 7.5% year-over-year in Q2 2026 and has beaten earnings estimates in two of the last three quarters. Recent positive sentiment follows the company's 10th store announcement and a golden cross technical pattern. However, the company continues to report net losses with a -2.49% net income margin and carries significant debt with a 95.11% debt-to-asset ratio.

Wayfair presents a mixed investment case with strong revenue momentum and market share gains offset by persistent profitability challenges. The consensus price target of $125.14 suggests 25% upside potential, supported by 53.57% analyst buy ratings. Key risks include ongoing net losses, high leverage, and consumer spending sensitivity. The stock's technical strength and expansion initiatives provide catalysts, but profitability improvement remains critical for sustained upside.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE

About Wayfair Inc

Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.

Read more on W